Global and Regional Adhesion Barrier

Adhesion Barrier Comprehensive Study by Type (Synthetic Adhesion Barrier, Natural Adhesion Barrier), Application (Gynecological Surgeries, Cardiovascular Surgeries, Neurological Surgeries, Orthopedic Surgeries, General/Abdominal Surgeries), Formulation Type (Film Formulations, Liquid Formulations, Gel Formulations) Players and Region - Global Market Outlook to 2027

Adhesion Barrier Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 7.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Adhesion Barrier are the devices which are used in the field of medicine. These devices come with the intention to stop or decrease adhesions in post-operative complications. Adhesion barriers have risen as a medical implant which helps in reducing the incidence of post-operative adhesions in patients after the surgery. Adhesion barriers are most used in surgery like abdominal surgery, gynecological surgery, or pelvic laparotomy. Increasing diseases coupled with improved treatment have apparently increased the demand for adhesion barrier devices globally. According to AMA Research, the market for Adhesion Barrier is expected to register a CAGR of 7.6% during the forecast period to 2027. This growth is primarily driven by Rising Geriatric Population across the Globe .

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Volume UnitUnit
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Medical Devices sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Johnson & Johnson (J&J) (United States), Sanofi (France), Baxter International (United States), C.R. Bard (United States), Integra LifeSciences (United States), Anika Therapeutics (United States), Atrium Medical Corporation (United States), FzioMed (United States), MAST Biosurgery (Switzerland) and Innocoll Holdings (Ireland), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In 2020, Baxter International, one of the leading biopharmaceutical companies, completed the acquisition of Seprafilm Adhesion Barrier.
In 2021, Gunze Launches TENALEAF' Absorbent Adhesive Barrier in Japan., In 2020, Baxter International, One of the Leading Biopharmaceutical Companies Completes Acquisition of Seprafilm Adhesion Barrier and In 2020, Anika Therapeutics has launched a series of six products covering orthopedic and sports medicine related surgeries. All six minimally invasive devices are FDA-approved to face challenges such as rotator cuff repair, arthritis injury treatment, and arthroscopic knee repair.The leading player existing in the market are Sanofi S.A.; Becton Dickinson and Company; Baxter International, Inc.; Johnson and Johnson; Anika Therapeutics, Inc.; FzioMed, Inc; Mast Biosurgery, Inc.; Innocoll Holdings PLC; and Atrium Medical Corporation . Rising product launches, mergers and acquisitions, partnerships, and technological collaboration are the principal strategies adopted through most of these gamers to hold their market share.

Adhesion Barrier Market Dynamics:
AttributesDetails
Growth Drivers
  • Rising Geriatric Population across the Globe
  • Growth in the Number of Sports-Related, Hand and Wrist Injuries
  • Increase in the Volume of Surgeries World-Widely
  • Increasing Awareness about the Medical Implications of Adhesion
Influencing Trends
  • Increasing Adoption of Usage of Synthetic Adhesion
  • Increased Adoption of Anti-Adhesive Products among Healthcare Providers
Restraints
  • Reluctance towards the Usage of Adhesion Barriers among Surgeons
  • High Prices of Adhesion Barriers
Road Blocks / Challenges
  • Limited Technological Developments Due to Stringent Regulations
Gaps & Opportunities
  • Growth of Rapid Advancement in the Healthcare Sector
  • Untapped Emerging Markets in Both Developed and Developing
  • Growing Awareness for Better Healthcare


AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Adhesion Barrier Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Adhesion Barrier Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Adhesion Barrier players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Adhesion Barrier Study Sheds Light on
— The Adhesion Barrier Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Adhesion Barrier industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Adhesion Barrier industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Synthetic Adhesion Barrier
  • Natural Adhesion Barrier
By Application
  • Gynecological Surgeries
  • Cardiovascular Surgeries
  • Neurological Surgeries
  • Orthopedic Surgeries
  • General/Abdominal Surgeries
By Formulation Type
  • Film Formulations
  • Liquid Formulations
  • Gel Formulations

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Geriatric Population across the Globe
      • 3.2.2. Growth in the Number of Sports-Related, Hand and Wrist Injuries
      • 3.2.3. Increase in the Volume of Surgeries World-Widely
      • 3.2.4. Increasing Awareness about the Medical Implications of Adhesion
    • 3.3. Market Challenges
      • 3.3.1. Limited Technological Developments Due to Stringent Regulations
    • 3.4. Market Trends
      • 3.4.1. Increasing Adoption of Usage of Synthetic Adhesion
      • 3.4.2. Increased Adoption of Anti-Adhesive Products among Healthcare Providers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Adhesion Barrier, by Type, Application, Formulation Type and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Adhesion Barrier (Value)
      • 5.2.1. Global Adhesion Barrier by: Type (Value)
        • 5.2.1.1. Synthetic Adhesion Barrier
        • 5.2.1.2. Natural Adhesion Barrier
      • 5.2.2. Global Adhesion Barrier by: Application (Value)
        • 5.2.2.1. Gynecological Surgeries
        • 5.2.2.2. Cardiovascular Surgeries
        • 5.2.2.3. Neurological Surgeries
        • 5.2.2.4. Orthopedic Surgeries
        • 5.2.2.5. General/Abdominal Surgeries
      • 5.2.3. Global Adhesion Barrier by: Formulation Type (Value)
        • 5.2.3.1. Film Formulations
        • 5.2.3.2. Liquid Formulations
        • 5.2.3.3. Gel Formulations
      • 5.2.4. Global Adhesion Barrier Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Adhesion Barrier (Volume)
      • 5.3.1. Global Adhesion Barrier by: Type (Volume)
        • 5.3.1.1. Synthetic Adhesion Barrier
        • 5.3.1.2. Natural Adhesion Barrier
      • 5.3.2. Global Adhesion Barrier by: Application (Volume)
        • 5.3.2.1. Gynecological Surgeries
        • 5.3.2.2. Cardiovascular Surgeries
        • 5.3.2.3. Neurological Surgeries
        • 5.3.2.4. Orthopedic Surgeries
        • 5.3.2.5. General/Abdominal Surgeries
      • 5.3.3. Global Adhesion Barrier by: Formulation Type (Volume)
        • 5.3.3.1. Film Formulations
        • 5.3.3.2. Liquid Formulations
        • 5.3.3.3. Gel Formulations
      • 5.3.4. Global Adhesion Barrier Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Adhesion Barrier (Price)
      • 5.4.1. Global Adhesion Barrier by: Type (Price)
  • 6. Adhesion Barrier: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson & Johnson (J&J) (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Baxter International (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. C.R. Bard (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Integra LifeSciences (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Anika Therapeutics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Atrium Medical Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. FzioMed (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. MAST Biosurgery (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Innocoll Holdings (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Adhesion Barrier Sale, by Type, Application, Formulation Type and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Adhesion Barrier (Value)
      • 7.2.1. Global Adhesion Barrier by: Type (Value)
        • 7.2.1.1. Synthetic Adhesion Barrier
        • 7.2.1.2. Natural Adhesion Barrier
      • 7.2.2. Global Adhesion Barrier by: Application (Value)
        • 7.2.2.1. Gynecological Surgeries
        • 7.2.2.2. Cardiovascular Surgeries
        • 7.2.2.3. Neurological Surgeries
        • 7.2.2.4. Orthopedic Surgeries
        • 7.2.2.5. General/Abdominal Surgeries
      • 7.2.3. Global Adhesion Barrier by: Formulation Type (Value)
        • 7.2.3.1. Film Formulations
        • 7.2.3.2. Liquid Formulations
        • 7.2.3.3. Gel Formulations
      • 7.2.4. Global Adhesion Barrier Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Adhesion Barrier (Volume)
      • 7.3.1. Global Adhesion Barrier by: Type (Volume)
        • 7.3.1.1. Synthetic Adhesion Barrier
        • 7.3.1.2. Natural Adhesion Barrier
      • 7.3.2. Global Adhesion Barrier by: Application (Volume)
        • 7.3.2.1. Gynecological Surgeries
        • 7.3.2.2. Cardiovascular Surgeries
        • 7.3.2.3. Neurological Surgeries
        • 7.3.2.4. Orthopedic Surgeries
        • 7.3.2.5. General/Abdominal Surgeries
      • 7.3.3. Global Adhesion Barrier by: Formulation Type (Volume)
        • 7.3.3.1. Film Formulations
        • 7.3.3.2. Liquid Formulations
        • 7.3.3.3. Gel Formulations
      • 7.3.4. Global Adhesion Barrier Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Adhesion Barrier (Price)
      • 7.4.1. Global Adhesion Barrier by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Adhesion Barrier: by Type(USD Million)
  • Table 2. Adhesion Barrier Synthetic Adhesion Barrier , by Region USD Million (2016-2021)
  • Table 3. Adhesion Barrier Natural Adhesion Barrier , by Region USD Million (2016-2021)
  • Table 4. Adhesion Barrier: by Application(USD Million)
  • Table 5. Adhesion Barrier Gynecological Surgeries , by Region USD Million (2016-2021)
  • Table 6. Adhesion Barrier Cardiovascular Surgeries , by Region USD Million (2016-2021)
  • Table 7. Adhesion Barrier Neurological Surgeries , by Region USD Million (2016-2021)
  • Table 8. Adhesion Barrier Orthopedic Surgeries , by Region USD Million (2016-2021)
  • Table 9. Adhesion Barrier General/Abdominal Surgeries , by Region USD Million (2016-2021)
  • Table 10. Adhesion Barrier: by Formulation Type(USD Million)
  • Table 11. Adhesion Barrier Film Formulations , by Region USD Million (2016-2021)
  • Table 12. Adhesion Barrier Liquid Formulations , by Region USD Million (2016-2021)
  • Table 13. Adhesion Barrier Gel Formulations , by Region USD Million (2016-2021)
  • Table 14. South America Adhesion Barrier, by Country USD Million (2016-2021)
  • Table 15. South America Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 16. South America Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 17. South America Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 18. Brazil Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 19. Brazil Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 20. Brazil Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 21. Argentina Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 22. Argentina Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 23. Argentina Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 24. Rest of South America Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 25. Rest of South America Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 26. Rest of South America Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 27. Asia Pacific Adhesion Barrier, by Country USD Million (2016-2021)
  • Table 28. Asia Pacific Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 29. Asia Pacific Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 30. Asia Pacific Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 31. China Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 32. China Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 33. China Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 34. Japan Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 35. Japan Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 36. Japan Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 37. India Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 38. India Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 39. India Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 40. South Korea Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 41. South Korea Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 42. South Korea Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 43. Taiwan Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 44. Taiwan Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 45. Taiwan Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 46. Australia Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 47. Australia Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 48. Australia Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 52. Europe Adhesion Barrier, by Country USD Million (2016-2021)
  • Table 53. Europe Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 54. Europe Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 55. Europe Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 56. Germany Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 57. Germany Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 58. Germany Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 59. France Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 60. France Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 61. France Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 62. Italy Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 63. Italy Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 64. Italy Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 65. United Kingdom Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 66. United Kingdom Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 67. United Kingdom Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 68. Netherlands Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 69. Netherlands Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 70. Netherlands Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 71. Rest of Europe Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 72. Rest of Europe Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 73. Rest of Europe Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 74. MEA Adhesion Barrier, by Country USD Million (2016-2021)
  • Table 75. MEA Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 76. MEA Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 77. MEA Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 78. Middle East Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 79. Middle East Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 80. Middle East Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 81. Africa Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 82. Africa Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 83. Africa Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 84. North America Adhesion Barrier, by Country USD Million (2016-2021)
  • Table 85. North America Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 86. North America Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 87. North America Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 88. United States Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 89. United States Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 90. United States Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 91. Canada Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 92. Canada Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 93. Canada Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 94. Mexico Adhesion Barrier, by Type USD Million (2016-2021)
  • Table 95. Mexico Adhesion Barrier, by Application USD Million (2016-2021)
  • Table 96. Mexico Adhesion Barrier, by Formulation Type USD Million (2016-2021)
  • Table 97. Adhesion Barrier Sales: by Type(Unit)
  • Table 98. Adhesion Barrier Sales Synthetic Adhesion Barrier , by Region Unit (2016-2021)
  • Table 99. Adhesion Barrier Sales Natural Adhesion Barrier , by Region Unit (2016-2021)
  • Table 100. Adhesion Barrier Sales: by Application(Unit)
  • Table 101. Adhesion Barrier Sales Gynecological Surgeries , by Region Unit (2016-2021)
  • Table 102. Adhesion Barrier Sales Cardiovascular Surgeries , by Region Unit (2016-2021)
  • Table 103. Adhesion Barrier Sales Neurological Surgeries , by Region Unit (2016-2021)
  • Table 104. Adhesion Barrier Sales Orthopedic Surgeries , by Region Unit (2016-2021)
  • Table 105. Adhesion Barrier Sales General/Abdominal Surgeries , by Region Unit (2016-2021)
  • Table 106. Adhesion Barrier Sales: by Formulation Type(Unit)
  • Table 107. Adhesion Barrier Sales Film Formulations , by Region Unit (2016-2021)
  • Table 108. Adhesion Barrier Sales Liquid Formulations , by Region Unit (2016-2021)
  • Table 109. Adhesion Barrier Sales Gel Formulations , by Region Unit (2016-2021)
  • Table 110. South America Adhesion Barrier Sales, by Country Unit (2016-2021)
  • Table 111. South America Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 112. South America Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 113. South America Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 114. Brazil Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 115. Brazil Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 116. Brazil Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 117. Argentina Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 118. Argentina Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 119. Argentina Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 120. Rest of South America Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 121. Rest of South America Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 122. Rest of South America Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 123. Asia Pacific Adhesion Barrier Sales, by Country Unit (2016-2021)
  • Table 124. Asia Pacific Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 125. Asia Pacific Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 126. Asia Pacific Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 127. China Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 128. China Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 129. China Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 130. Japan Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 131. Japan Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 132. Japan Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 133. India Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 134. India Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 135. India Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 136. South Korea Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 137. South Korea Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 138. South Korea Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 139. Taiwan Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 140. Taiwan Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 141. Taiwan Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 142. Australia Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 143. Australia Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 144. Australia Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 145. Rest of Asia-Pacific Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 146. Rest of Asia-Pacific Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 147. Rest of Asia-Pacific Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 148. Europe Adhesion Barrier Sales, by Country Unit (2016-2021)
  • Table 149. Europe Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 150. Europe Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 151. Europe Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 152. Germany Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 153. Germany Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 154. Germany Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 155. France Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 156. France Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 157. France Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 158. Italy Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 159. Italy Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 160. Italy Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 161. United Kingdom Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 162. United Kingdom Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 163. United Kingdom Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 164. Netherlands Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 165. Netherlands Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 166. Netherlands Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 167. Rest of Europe Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 168. Rest of Europe Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 169. Rest of Europe Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 170. MEA Adhesion Barrier Sales, by Country Unit (2016-2021)
  • Table 171. MEA Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 172. MEA Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 173. MEA Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 174. Middle East Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 175. Middle East Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 176. Middle East Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 177. Africa Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 178. Africa Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 179. Africa Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 180. North America Adhesion Barrier Sales, by Country Unit (2016-2021)
  • Table 181. North America Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 182. North America Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 183. North America Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 184. United States Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 185. United States Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 186. United States Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 187. Canada Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 188. Canada Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 189. Canada Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 190. Mexico Adhesion Barrier Sales, by Type Unit (2016-2021)
  • Table 191. Mexico Adhesion Barrier Sales, by Application Unit (2016-2021)
  • Table 192. Mexico Adhesion Barrier Sales, by Formulation Type Unit (2016-2021)
  • Table 193. Adhesion Barrier: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Adhesion Barrier: by Type(USD Million)
  • Table 205. Adhesion Barrier Synthetic Adhesion Barrier , by Region USD Million (2022-2027)
  • Table 206. Adhesion Barrier Natural Adhesion Barrier , by Region USD Million (2022-2027)
  • Table 207. Adhesion Barrier: by Application(USD Million)
  • Table 208. Adhesion Barrier Gynecological Surgeries , by Region USD Million (2022-2027)
  • Table 209. Adhesion Barrier Cardiovascular Surgeries , by Region USD Million (2022-2027)
  • Table 210. Adhesion Barrier Neurological Surgeries , by Region USD Million (2022-2027)
  • Table 211. Adhesion Barrier Orthopedic Surgeries , by Region USD Million (2022-2027)
  • Table 212. Adhesion Barrier General/Abdominal Surgeries , by Region USD Million (2022-2027)
  • Table 213. Adhesion Barrier: by Formulation Type(USD Million)
  • Table 214. Adhesion Barrier Film Formulations , by Region USD Million (2022-2027)
  • Table 215. Adhesion Barrier Liquid Formulations , by Region USD Million (2022-2027)
  • Table 216. Adhesion Barrier Gel Formulations , by Region USD Million (2022-2027)
  • Table 217. South America Adhesion Barrier, by Country USD Million (2022-2027)
  • Table 218. South America Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 219. South America Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 220. South America Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 221. Brazil Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 222. Brazil Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 223. Brazil Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 224. Argentina Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 225. Argentina Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 226. Argentina Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 227. Rest of South America Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 228. Rest of South America Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 229. Rest of South America Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 230. Asia Pacific Adhesion Barrier, by Country USD Million (2022-2027)
  • Table 231. Asia Pacific Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 232. Asia Pacific Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 233. Asia Pacific Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 234. China Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 235. China Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 236. China Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 237. Japan Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 238. Japan Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 239. Japan Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 240. India Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 241. India Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 242. India Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 243. South Korea Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 244. South Korea Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 245. South Korea Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 246. Taiwan Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 247. Taiwan Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 248. Taiwan Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 249. Australia Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 250. Australia Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 251. Australia Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 252. Rest of Asia-Pacific Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 253. Rest of Asia-Pacific Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 254. Rest of Asia-Pacific Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 255. Europe Adhesion Barrier, by Country USD Million (2022-2027)
  • Table 256. Europe Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 257. Europe Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 258. Europe Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 259. Germany Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 260. Germany Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 261. Germany Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 262. France Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 263. France Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 264. France Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 265. Italy Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 266. Italy Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 267. Italy Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 268. United Kingdom Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 269. United Kingdom Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 270. United Kingdom Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 271. Netherlands Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 272. Netherlands Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 273. Netherlands Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 274. Rest of Europe Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 275. Rest of Europe Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 276. Rest of Europe Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 277. MEA Adhesion Barrier, by Country USD Million (2022-2027)
  • Table 278. MEA Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 279. MEA Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 280. MEA Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 281. Middle East Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 282. Middle East Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 283. Middle East Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 284. Africa Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 285. Africa Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 286. Africa Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 287. North America Adhesion Barrier, by Country USD Million (2022-2027)
  • Table 288. North America Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 289. North America Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 290. North America Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 291. United States Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 292. United States Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 293. United States Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 294. Canada Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 295. Canada Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 296. Canada Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 297. Mexico Adhesion Barrier, by Type USD Million (2022-2027)
  • Table 298. Mexico Adhesion Barrier, by Application USD Million (2022-2027)
  • Table 299. Mexico Adhesion Barrier, by Formulation Type USD Million (2022-2027)
  • Table 300. Adhesion Barrier Sales: by Type(Unit)
  • Table 301. Adhesion Barrier Sales Synthetic Adhesion Barrier , by Region Unit (2022-2027)
  • Table 302. Adhesion Barrier Sales Natural Adhesion Barrier , by Region Unit (2022-2027)
  • Table 303. Adhesion Barrier Sales: by Application(Unit)
  • Table 304. Adhesion Barrier Sales Gynecological Surgeries , by Region Unit (2022-2027)
  • Table 305. Adhesion Barrier Sales Cardiovascular Surgeries , by Region Unit (2022-2027)
  • Table 306. Adhesion Barrier Sales Neurological Surgeries , by Region Unit (2022-2027)
  • Table 307. Adhesion Barrier Sales Orthopedic Surgeries , by Region Unit (2022-2027)
  • Table 308. Adhesion Barrier Sales General/Abdominal Surgeries , by Region Unit (2022-2027)
  • Table 309. Adhesion Barrier Sales: by Formulation Type(Unit)
  • Table 310. Adhesion Barrier Sales Film Formulations , by Region Unit (2022-2027)
  • Table 311. Adhesion Barrier Sales Liquid Formulations , by Region Unit (2022-2027)
  • Table 312. Adhesion Barrier Sales Gel Formulations , by Region Unit (2022-2027)
  • Table 313. South America Adhesion Barrier Sales, by Country Unit (2022-2027)
  • Table 314. South America Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 315. South America Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 316. South America Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 317. Brazil Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 318. Brazil Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 319. Brazil Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 320. Argentina Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 321. Argentina Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 322. Argentina Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 323. Rest of South America Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 324. Rest of South America Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 325. Rest of South America Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 326. Asia Pacific Adhesion Barrier Sales, by Country Unit (2022-2027)
  • Table 327. Asia Pacific Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 328. Asia Pacific Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 329. Asia Pacific Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 330. China Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 331. China Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 332. China Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 333. Japan Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 334. Japan Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 335. Japan Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 336. India Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 337. India Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 338. India Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 339. South Korea Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 340. South Korea Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 341. South Korea Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 342. Taiwan Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 343. Taiwan Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 344. Taiwan Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 345. Australia Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 346. Australia Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 347. Australia Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 348. Rest of Asia-Pacific Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 349. Rest of Asia-Pacific Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 350. Rest of Asia-Pacific Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 351. Europe Adhesion Barrier Sales, by Country Unit (2022-2027)
  • Table 352. Europe Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 353. Europe Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 354. Europe Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 355. Germany Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 356. Germany Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 357. Germany Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 358. France Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 359. France Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 360. France Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 361. Italy Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 362. Italy Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 363. Italy Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 364. United Kingdom Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 365. United Kingdom Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 366. United Kingdom Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 367. Netherlands Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 368. Netherlands Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 369. Netherlands Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 370. Rest of Europe Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 371. Rest of Europe Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 372. Rest of Europe Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 373. MEA Adhesion Barrier Sales, by Country Unit (2022-2027)
  • Table 374. MEA Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 375. MEA Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 376. MEA Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 377. Middle East Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 378. Middle East Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 379. Middle East Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 380. Africa Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 381. Africa Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 382. Africa Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 383. North America Adhesion Barrier Sales, by Country Unit (2022-2027)
  • Table 384. North America Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 385. North America Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 386. North America Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 387. United States Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 388. United States Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 389. United States Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 390. Canada Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 391. Canada Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 392. Canada Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 393. Mexico Adhesion Barrier Sales, by Type Unit (2022-2027)
  • Table 394. Mexico Adhesion Barrier Sales, by Application Unit (2022-2027)
  • Table 395. Mexico Adhesion Barrier Sales, by Formulation Type Unit (2022-2027)
  • Table 396. Adhesion Barrier: by Type(USD/Units)
  • Table 397. Research Programs/Design for This Report
  • Table 398. Key Data Information from Secondary Sources
  • Table 399. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Adhesion Barrier: by Type USD Million (2016-2021)
  • Figure 5. Global Adhesion Barrier: by Application USD Million (2016-2021)
  • Figure 6. Global Adhesion Barrier: by Formulation Type USD Million (2016-2021)
  • Figure 7. South America Adhesion Barrier Share (%), by Country
  • Figure 8. Asia Pacific Adhesion Barrier Share (%), by Country
  • Figure 9. Europe Adhesion Barrier Share (%), by Country
  • Figure 10. MEA Adhesion Barrier Share (%), by Country
  • Figure 11. North America Adhesion Barrier Share (%), by Country
  • Figure 12. Global Adhesion Barrier: by Type Unit (2016-2021)
  • Figure 13. Global Adhesion Barrier: by Application Unit (2016-2021)
  • Figure 14. Global Adhesion Barrier: by Formulation Type Unit (2016-2021)
  • Figure 15. South America Adhesion Barrier Share (%), by Country
  • Figure 16. Asia Pacific Adhesion Barrier Share (%), by Country
  • Figure 17. Europe Adhesion Barrier Share (%), by Country
  • Figure 18. MEA Adhesion Barrier Share (%), by Country
  • Figure 19. North America Adhesion Barrier Share (%), by Country
  • Figure 20. Global Adhesion Barrier: by Type USD/Units (2016-2021)
  • Figure 21. Global Adhesion Barrier share by Players 2021 (%)
  • Figure 22. Global Adhesion Barrier share by Players (Top 3) 2021(%)
  • Figure 23. Global Adhesion Barrier share by Players (Top 5) 2021(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Johnson & Johnson (J&J) (United States) Revenue, Net Income and Gross profit
  • Figure 26. Johnson & Johnson (J&J) (United States) Revenue: by Geography 2021
  • Figure 27. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi (France) Revenue: by Geography 2021
  • Figure 29. Baxter International (United States) Revenue, Net Income and Gross profit
  • Figure 30. Baxter International (United States) Revenue: by Geography 2021
  • Figure 31. C.R. Bard (United States) Revenue, Net Income and Gross profit
  • Figure 32. C.R. Bard (United States) Revenue: by Geography 2021
  • Figure 33. Integra LifeSciences (United States) Revenue, Net Income and Gross profit
  • Figure 34. Integra LifeSciences (United States) Revenue: by Geography 2021
  • Figure 35. Anika Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 36. Anika Therapeutics (United States) Revenue: by Geography 2021
  • Figure 37. Atrium Medical Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 38. Atrium Medical Corporation (United States) Revenue: by Geography 2021
  • Figure 39. FzioMed (United States) Revenue, Net Income and Gross profit
  • Figure 40. FzioMed (United States) Revenue: by Geography 2021
  • Figure 41. MAST Biosurgery (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. MAST Biosurgery (Switzerland) Revenue: by Geography 2021
  • Figure 43. Innocoll Holdings (Ireland) Revenue, Net Income and Gross profit
  • Figure 44. Innocoll Holdings (Ireland) Revenue: by Geography 2021
  • Figure 45. Global Adhesion Barrier: by Type USD Million (2022-2027)
  • Figure 46. Global Adhesion Barrier: by Application USD Million (2022-2027)
  • Figure 47. Global Adhesion Barrier: by Formulation Type USD Million (2022-2027)
  • Figure 48. South America Adhesion Barrier Share (%), by Country
  • Figure 49. Asia Pacific Adhesion Barrier Share (%), by Country
  • Figure 50. Europe Adhesion Barrier Share (%), by Country
  • Figure 51. MEA Adhesion Barrier Share (%), by Country
  • Figure 52. North America Adhesion Barrier Share (%), by Country
  • Figure 53. Global Adhesion Barrier: by Type Unit (2022-2027)
  • Figure 54. Global Adhesion Barrier: by Application Unit (2022-2027)
  • Figure 55. Global Adhesion Barrier: by Formulation Type Unit (2022-2027)
  • Figure 56. South America Adhesion Barrier Share (%), by Country
  • Figure 57. Asia Pacific Adhesion Barrier Share (%), by Country
  • Figure 58. Europe Adhesion Barrier Share (%), by Country
  • Figure 59. MEA Adhesion Barrier Share (%), by Country
  • Figure 60. North America Adhesion Barrier Share (%), by Country
  • Figure 61. Global Adhesion Barrier: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Johnson & Johnson (J&J) (United States)
  • Sanofi (France)
  • Baxter International (United States)
  • C.R. Bard (United States)
  • Integra LifeSciences (United States)
  • Anika Therapeutics (United States)
  • Atrium Medical Corporation (United States)
  • FzioMed (United States)
  • MAST Biosurgery (Switzerland)
  • Innocoll Holdings (Ireland)
Additional players considered in the study are as follows:
Betatech Medical (Turkey) , SyntheMed (United States) , Aziyo Biologics (United States) , Biom’up (France) , Terumo Corporation (Japan) , BMI Korea Co. (South Korea)
Select User Access Type

Key Highlights of Report


Aug 2022 158 Pages 89 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and Regional Adhesion Barrier Quantitative research analysis
Global and Regional Adhesion Barrier Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Adhesion Barrier Market are Johnson & Johnson (J&J) (United States), Sanofi (France), Baxter International (United States), C.R. Bard (United States), Integra LifeSciences (United States), Anika Therapeutics (United States), Atrium Medical Corporation (United States), FzioMed (United States), MAST Biosurgery (Switzerland) and Innocoll Holdings (Ireland) etc.
Gynecological Surgeries segment in Global market to hold robust market share owing to "Rising Geriatric Population across the Globe ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Adhesion Barrier market throughout the forecasted period.

Know More About Global and Regional Adhesion Barrier Report?

Have a Query? Click Here

Other Related Reports

Spine Surgery Products Comprehensive Study by Type (Spinal Fusion Products, Non-fusion Products), Application (Open Surgery, Minimally Invasive Surgery, Channel, By Channels, Market has been segmente...
$ 3800
Dental lights Comprehensive Study by Type (LED Lights, Halogen Lights), Application (Hospitals, Dental Clinics), Technology (Fixed Dental Lights, Mobile Dental Lights), Distribution Channel (Online, ...
$ 3500
Medical Film Scanner Comprehensive Study by Type (Dental X-ray film scanner, Standard radiographic film scanner, Mammography film scanner), Application (Disease detection, Thymus protection, Tooth pr...
$ 3650
Microcatheter Comprehensive Study by Type (Delivery Microcatheters, Aspiration Microcatheters, Diagnostic Microcatheters, Steerable Microcatheters), Application (Cardiovascular, Neurovascular, Periph...
$ 3750
Orthopedic Trauma Devices Comprehensive Study by Type (Internal Fixation Trauma Devices (Screws, Plates, Nails, Patient-specific Implants, and Others), External Fixation Trauma Devices (Rigid Casts, ...
$ 3750
CT Scanner Comprehensive Study by Type (Stationary CT scanners, Portable CT scanners), Application (Human Diagnostics, Veterinary, Research, Other), Technology (High-slice CT, Mid-slice CT, Low-slice...
$ 3750